niraparib (Rx)

Brand and Other Names:Zejula

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule

  • 100mg

Ovarian Cancer

Recurrent ovarian cancer

  • Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to platinum-based chemotherapy
  • Start treatment no later than 8 weeks after their most recent platinum-containing regimen
  • 300 mg PO qDay
  • Continue until disease progression or unacceptable toxicity

Advanced ovarian cancer

First-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy

Start treatment no later than 12 weeks after their most recent platinum-containing regimen

<77 kg (170 lbs) OR with a platelet count <150,000/μL: 200 mg PO qDay

≥77 kg AND who have a platelet count ≥150,000/μL: 300 mg PO qDay

Continue until disease progression or unacceptable toxicity

Dosage Modifications

Dose reductions

  • 300 mg starting dose
    • First dose reduction: 200 mg/day
    • Second dose reduction: 100 mg/day
    • Discontinue if further dose reduction <100 mg/day required
  • 200 mg starting dose
    • First dose reduction: 100 mg/day
    • Discontinue if further dose reduction <100 mg/day required

Nonhematologic adverse reactions

  • Persistent Grade ≥3 despite medical management
    • Withhold for a maximum of 28 days or until adverse reaction resolves
    • Resume at reduced dose level
  • Grade ≥3 reactions lasting >28 days and taking niraparib 100 mg/day
    • Discontinue treatment

Hematologic adverse reactions

  • Platelet count <1000,000/mcL
    • First occurrence: Withhold up to 28 days and monitor blood cell counts weekly until platelets ≥100,000/mcL; resume at same or reduced dose; if platelet count is <75,000/mcL, resume at reduced dose
    • Second occurrence: Withhold up to 28 days and monitor blood cell counts weekly until platelets ≥100,000/mcL; resume at reduced dose; discontinue if platelet count has not returned to acceptable levels within 28 days or if the patient is already on 100 mg/day
  • Neutrophil count <1000/mcL or hemoglobin <8 g/dL
    • Withhold up to 28 days and monitor blood cell counts weekly until neutrophils ≥1500/mcL or hemoglobin ≥9 g/dL; resume at reduced dose
    • Discontinue if neutrophils and/or hemoglobin have not returned to acceptable levels within 28 days or if the patient is already on 100 mg/day
  • Hematologic adverse reaction requiring transfusion
    • Platelet count ≤10,000/mcL: Consider platelet transfusion
    • If other risk factors exist (eg anticoagulants, antiplatelets), consider interrupting anticoagulants or antiplatelet drugs and/or transfuse at a higher platelet count
    • Resume at a reduced dose

Renal impairment

  • Mild-to-moderate (CrCl ≥30 mL/min): No dose adjustment required
  • Severe or ESRD: Not studied

Hepatic impairment

  • Mild (total bilirubin [TB] <1.5x ULN and any AST level): No dosage adjustment necessary
  • Moderate [TB 1.5x-3x ULN and any AST): Reduce starting dose to 200 mg PO qDay
  • Severe [TB >3x ULN and any AST): Not established

Dosing Considerations

Patient selection

  • For maintenance treatment of recurrent ovarian cancer
  • Select based on deleterious or suspected deleterious BRCA mutation
  • Information on FDA-approved tests is available at: http://www.fda.gov/CompanionDiagnostics

Safety and efficacy not established

Next:

Adverse Effects

Adverse effects include all grades unless otherwise stated

>10%

Nausea (74%)

Thrombocytopenia (61%)

Fatigue/asthenia (57%)

Fatigue (55%)

Anemia (50%)

Constipation (40%)

Musculoskeletal pain (36%)

Vomiting (34%)

Abdominal pain/distention (33%)

Neutropenia (30%)

Thrombocytopenia, grades 3 or 4 (29%)

Insomnia (27%)

Headache (26%)

Anemia, grades 3 or 4 (25%)

Decreased appetite (24%)

Nasopharyngitis (23%)

Rash (21%)

Hypertension (20%)

Neutropenia, grades 3 or 4 (20%)

Mucositis/stomatitis (20%)

Diarrhea (20%)

Dyspepsia (20%)

Myalgia (19%)

Back pain (18%)

Dyspepsia (18%)

Dizziness (18%)

Leukopenia (17%)

Cough (16%)

Acute kidney injury (13%)

UTI (13%)

Arthralgia (13%)

Anxiety (11%)

Hypomagnesemia (11%)

1-10%

Palpitations (10%)

Dry mouth (10%)

AST/ALT elevation (10%)

Dysgeusia (10%)

Hypertension, grade 3 or 4 (9%)

Leukopenia, grades 3 or 4 (5%)

Postmarketing Reports

Immune system disorders: Hypersensitivity (including anaphylaxis)

Nervous system disorders: Posterior reversible encephalopathy syndrome (PRES)

Psychiatric disorders: Confusional state/disorientation, hallucination, cognitive impairment (eg, memory impairment, concentration impairment)

Respiratory, thoracic, and mediastinal disorders: Non-infectious pneumonitis

Skin and SC tissue disorders: Photosensitivity

Hematologic disorders: Neutropenic infection, neutropenic sepsis, febrile neutropenia, pancytopenia

Vascular disorders: Hypertensive crisis

Previous
Next:

Warnings

Contraindications

None

Cautions

Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), including cases with fatal outcome, reported; for suspected MDS/AML or prolonged hematological toxicities, refer the patient to a hematologist for further evaluation; discontinue drug if MDS/AML confirmed

Hypertension and hypertensive crisis reported; monitor BP and HR monthly for the first year and periodically thereafter during treatment; medically manage hypertension with antihypertensive medications and niraparib dose adjustment

Capsules contain FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons; incidence of sensitivity in the general population is low, frequently seen in patients who also have aspirin hypersensitivity

Based on its mechanism of action, can cause fetal harm if administered to a pregnant woman (see Pregnancy)

Encephalopathy syndrome

  • Posterior reversible encephalopathy syndrome (PRES) reported; signs and symptoms of PRES include seizure, headache, altered mental status, visual disturbance, or cortical blindness, with or without associated hypertension
  • A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging
  • Monitor all patients receiving treatment for signs and symptoms of PRES; if PRES is suspected, promptly discontinue drug and administer appropriate treatment
  • The safety of reinitiating treatment in patients previously experiencing PRES not known

Bone marrow suppression

  • May cause bone marrow suppression resulting in hematologic toxicities (eg, thrombocytopenia, anemia, neutropenia)
  • Do not initiate until patients have recovered from hematological toxicities caused by previous chemotherapy (grade ≤1)
  • Monitor complete blood cell counts weekly for the first month, monthly for the next 11 months of treatment, and periodically after this time (also see Dosage Modifications)
Previous
Next:

Pregnancy

Pregnancy

Niraparib has the potential to cause teratogenicity and/or embryo-fetal death since niraparib is genotoxic and targets actively dividing cells in animals and patients (eg, bone marrow)

A pregnancy test is recommended for females of reproductive potential prior to initiating drug

Based on animal studies, may impair fertility in males of reproductive potential

Contraception

  • Advise females of reproductive potential to use effective contraception during treatment for at least 6 months following the last dose

Lactation

No data are available regarding the presence of niraparib or its metabolites in human milk, or on its effects on the breastfed infant or milk production

Owing to the potential for serious adverse reactions in breastfed infants, advise a lactating woman not to breastfeed during treatment and for 1 month after receiving the final dose

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Poly (ADP-ribose) polymerase (PARP) inhibitor; niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage, apoptosis, and cell death

Absorption

Bioavailability: 73%

Peak plasma time: 3 hr

Peak plasma concentration: 804 ng/mL

Distribution

Protein bound: 83%

Vd: 1200 L

Metabolism

Metabolized primarily by carboxylesterases (CEs) to form a major inactive metabolite, which subsequently undergoes glucuronidation

Elimination

Half-life: 36 hr

Excretion: 47.5% urine; 38.8% feces

Previous
Next:

Administration

Oral Administration

May take with or without food

Take dose at about the same time each day

Swallow each capsule whole

Bedtime administration may be a potential method for managing nausea

Missed or vomited dose

  • Take next dose at its regularly scheduled time
  • Do not take an additional dose

Storage

Store at 20-25°C (68-77°F); excursions are permitted between 15-30°C (59-86°F)

Previous
Next:

Images

BRAND FORM. UNIT PRICE PILL IMAGE
Zejula oral
-
100 mg capsule

Copyright © 2010 First DataBank, Inc.

Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.